Ardmore ShippingNYSE: ASC

The third quarter results were not that bad. Compared to 3Q23, Ardmore realized higher revenue, EBITDA, and EPS. According to the company's estimates, an additional $10,000 per day equals an annual increase of about $2.25 in EPS increase and nearly $100 million in FCF growth. As of November 06, Ardmore holds $47.6 million cash and owes $30.0 million total debt. Its Total Debt-to-Equity ratio is 8.1%.

Ardmore Shipping's strategic advantage lies in its eco-friendly fleet and operational flexibility, enabling it to capitalize on shifting market dynamics between chemical and petroleum products. Q3 results showed double-digit growth in revenue and EPS, along with improved TCE rates and record-low breakeven levels. Ardmore's balance sheet has strengthened, reducing debt from $97 million to $23 million, and rewarding shareholders with consecutive dividend payouts.

-Phase III trial enrolled a total of 480 patients with moderate to severe acne -Topline results expected in the second quarter 2025 HANGZHOU, China , Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat) o nce-daily oral tablet for treatment of moderate to severe acne. The first patient was enrolled on January 24, 2024.

Recently, Zacks.com users have been paying close attention to Ardmore Shipping (ASC). This makes it worthwhile to examine what the stock has in store.

Data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) showed that ASC47, via subcutaneous (SQ) injection ,  demonstrated a half-life of 21 days , supporting once-monthly administration in patients with obesity In multiple pre-clinical studies using the diet-induced obese (DIO) mouse model, ASC47 demonstrated healthy weight loss (muscle-preserving weight loss) Compared to semaglutide in a head-to-head pre-clinical study using a DIO mouse model, ASC47 reduced total fat mass (-63.5%), statistically and significantly more than semaglutide (-39.6%). In the same study, ASC47 statistically and significantly increased total muscle mass (+5.8%), while semaglutide decreased total muscle mass (-9.3%).

HAMILTON, Bermuda , Nov. 6, 2024 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore", the "Company" or "we") today announced results for the three and nine months ended September 30, 2024. Highlights and Recent Activity Reported net income and Adjusted earnings of $23.3 million for the three months ended September 30, 2024, or $0.55 earnings and Adjusted earnings per basic share and diluted share, compared to net income attributable to common stockholders and Adjusted earnings of $20.3 million, or $0.49 earnings and Adjusted earnings per basic share and diluted share for the three months ended September 30, 2023.

In the latest trading session, Ardmore Shipping (ASC) closed at $14.16, marking a -1.8% move from the previous day.

The latest trading day saw Ardmore Shipping (ASC) settling at $16.68, representing a +0.06% change from its previous close.

Ardmore Shipping (ASC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.